Champions Oncology Inc (CSBR)

[Milburn D]

Champions Oncology Reports Changes to Board of Directors

HACKENSACK, Mar 05, 2013 (GLOBE NEWSWIRE via COMTEX) -- Champions Oncology,
Inc. (OTC:CSBR) is pleased to announce the appointments of Dan Mendelson and
Arthur G. ("Bart") Epker, III to the Board of Directors of Champions Oncology,
Inc.

Dan Mendelson is CEO and founder of Avalere Health, a strategic advisory company
focused on devising innovative solutions to complex healthcare problems. The
firm's customer base includes Fortune 500 healthcare companies, provider
organizations, medical foundations, and government. Dan is also currently
Adjunct Professor of Business Administration at The Fuqua School of Business at
Duke University and sits on the boards of Coventry Health Care Inc. and HMS
Holdings Corp. From 1998 to 2000, Dan served as Associate Director for Health at
the Office of Management and Budget (OMB). Prior to joining OMB, Dan was Senior
Vice President of The Lewin Group and Director of the Medical Technology
practice. He holds an undergraduate degree in economics and viola performance
from Oberlin College, and a M.P.P. from the Kennedy School of Government at
Harvard University.

Bart Epker is a Vice President and partner of PAR Capital Management, Inc., an
investment adviser that manages PAR Investment Partners, L.P., a private
investment fund. Bart is a member of the boards of directors of Pure Cycle
Corporation, the Steppingstone Foundation, and the Winsor School and is on the
Honors Alumni Council at the University of Michigan. Prior to joining PAR
Capital in 1992, Bart worked at TA Associates, a private equity firm. He
received his undergraduate degree in computer science and economics with highest
distinction from the University of Michigan (1983) and his Masters of Business
Administration from Harvard Business School (1987). PAR Investment Partners
purchased common stock and warrants of the Company in a private placement on
January 28, 2013. As part of that transaction, the Company agreed to appoint a
designee of PAR Investment Partners, to its board of directors. Bart is the
designee chosen by PAR Investment Partners.

Dr. David Sidransky, Chairman of the Board of Directors, commented, "The
addition of such outstanding directors like Dan and Bart is an important
milestone in the continued evolution of Champions to meet the market needs. We
are excited to be welcoming them to the board and look forward to their guidance
through the continued strategic, operational and financial growth of the
company."

In conjunction with these appointments, Ana Stancic has resigned from the Board
of Directors. Scott Tobin, a current director of the company, will assume the
role of Chairman of the Audit Committee.

Dr. David Sidransky, Chairman of the Board of Directors commented, "We thank Ana
for the years of service she provided the company. Her insights and experience
have helped set the strategic direction and ensured financial discipline at the
company."

Ana Stancic commented, "It has been very rewarding to contribute to the progress
the company has made during my board tenure. I look forward to watching the
company progress in the future from the solid foundation that has been built
over time."

About Champions Oncology, Inc.

Champions Oncology, Inc. is engaged in the development of advanced technology
solutions and services to personalize the development and use of oncology drugs.
The Company's TumorGraft Technology Platform is a novel approach to
personalizing cancer care based upon the implantation of primary human tumors in
immune deficient mice followed by propagation of the TumorGrafts in a manner
that preserves the biological characteristics in order to determine the efficacy
of a treatment regimen. The Company uses this technology to offer solutions for
Personalized Oncology Solutions, which guides the development of personalized
treatment plans, and Translational Oncology Solutions, which assists
pharmaceutical and biotechnology companies seeking personalized approaches to
drug development to lower the cost and increase the speed of drug development.

For more information, visit www.championsoncology.com.

This press release may contain "forward-looking statements" (within the meaning
of the Private Securities Litigation Act of 1995) that inherently involve risk
and uncertainties. Champions Oncology generally uses words such as "believe,"
"may," "could," "will," "intend," "expect," "anticipate," "plan," and similar
expressions to identify forward-looking statements. One should not place undue
reliance on these forward-looking statements. The Company's actual results could
differ materially from those anticipated in the forward-looking statements for
many unforeseen factors. See Champions Oncology's Form 10-K for the fiscal year
ended April 30, 2012 for a discussion of such risks, uncertainties and other
factors. Although the Company believes the expectations reflected in the
forward-looking statements are reasonable, they relate only to events as of the
date on which the statements are made, and Champions Oncology's future results,
levels of activity, performance or achievements may not meet these expectations.
The Company does not intend to update any of the forward-looking statements
after the date of this press release to conform these statements to actual
results or to changes in Champions Oncology's expectations, except as required
by law.



CONTACT: Gary Gemignani

Champions Oncology, Inc.

201-808-8408

[e-mail]



Lauren Kwiecinski

The Trout Group LLC

646-378-2934

[e-mail]

http://www.globenewswire.com/newsroom/ti?nf=MTMjMTAwMjQwMTYjMjM4NzM=




(C) Copyright 2013 GlobeNewswire, Inc. All rights reserved.

-0-




KEYWORD: HACKENSACK

INDUSTRY KEYWORD: Healthcare & Medical Services

SUBJECT CODE: Directors and Officers

BIOTECHNOLOGY

MEDICAL

PHARMACEUTICALS

MANAGEMENT CHANGES